SMT201400177B - Diagnosi e trattamenti di carcinoma basati sul genotipo di odc1 - Google Patents

Diagnosi e trattamenti di carcinoma basati sul genotipo di odc1

Info

Publication number
SMT201400177B
SMT201400177B SM201400177T SM201400177T SMT201400177B SM T201400177 B SMT201400177 B SM T201400177B SM 201400177 T SM201400177 T SM 201400177T SM 201400177 T SM201400177 T SM 201400177T SM T201400177 B SMT201400177 B SM T201400177B
Authority
SM
San Marino
Prior art keywords
diagnosis
treatment
carcinoma based
odc1 genotype
odc1
Prior art date
Application number
SM201400177T
Other languages
English (en)
Italian (it)
Inventor
Eugene Gerner
Jason Zell
Christine Mclaren
Hoda Anton-Culver
Patricia A Thompson
Frank Meyskens
Original Assignee
Univ Arizona State
Univ California Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State, Univ California Corp filed Critical Univ Arizona State
Publication of SMT201400177B publication Critical patent/SMT201400177B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM201400177T 2009-05-14 2014-11-21 Diagnosi e trattamenti di carcinoma basati sul genotipo di odc1 SMT201400177B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21621609P 2009-05-14 2009-05-14
US21768209P 2009-06-03 2009-06-03
US21767909P 2009-06-03 2009-06-03
PCT/US2010/034974 WO2010132817A1 (en) 2009-05-14 2010-05-14 Carcinoma diagnosis and treatments, based on odc1 genotype

Publications (1)

Publication Number Publication Date
SMT201400177B true SMT201400177B (it) 2015-01-15

Family

ID=43085356

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400177T SMT201400177B (it) 2009-05-14 2014-11-21 Diagnosi e trattamenti di carcinoma basati sul genotipo di odc1

Country Status (15)

Country Link
US (4) US8329636B2 (enExample)
EP (1) EP2430452B1 (enExample)
JP (2) JP6083860B2 (enExample)
CN (1) CN102483415B (enExample)
AU (1) AU2010248803B2 (enExample)
CA (1) CA2761946A1 (enExample)
DK (1) DK2430452T3 (enExample)
ES (1) ES2507145T3 (enExample)
HR (1) HRP20140887T1 (enExample)
IL (1) IL216369B (enExample)
PL (1) PL2430452T3 (enExample)
PT (1) PT2430452E (enExample)
SI (1) SI2430452T1 (enExample)
SM (1) SMT201400177B (enExample)
WO (1) WO2010132817A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2430452E (pt) 2009-05-14 2014-09-30 Univ Arizona State Diagnóstico e tratamentos de carcinoma com base no genótipo odc1
CA2799431A1 (en) * 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
WO2012088146A2 (en) * 2010-12-20 2012-06-28 The University Of Notre Dame Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
US20120172244A1 (en) 2010-12-20 2012-07-05 Steven Buechler Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
LT2912193T (lt) * 2012-10-29 2018-12-27 Arizona Board Of Regents On Behalf Of University Of Arizona Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi
WO2015195120A1 (en) * 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
US20190046484A1 (en) * 2015-02-12 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
CA2980078C (en) * 2015-03-16 2024-03-12 Personal Genome Diagnostics Inc. Systems and methods for analyzing nucleic acid
MX390899B (es) 2015-10-30 2025-03-21 Cancer Prevention Pharmaceuticals Inc Formulación de combinación de dosis fija, eflornitina y sulindaco.
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
JP6963271B2 (ja) * 2017-01-20 2021-11-05 国立大学法人東海国立大学機構 イヌの遺伝性消化管腫瘍症の遺伝子診断法
CN114096240A (zh) 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
WO1995021271A1 (en) 1994-02-07 1995-08-10 Molecular Tool, Inc. Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
EP1067919A1 (en) 1998-03-28 2001-01-17 THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA Dfmo and sulindac combination in cancer chemoprevention
US7700568B2 (en) * 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
JP2002533404A (ja) * 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
US6573290B1 (en) 1999-05-17 2003-06-03 Ilex Oncology, Inc. DFMO and celecoxib in combination for cancer chemoprevention and therapy
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
JP2004506683A (ja) 2000-08-24 2004-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア α−ジフルオロメチルオルニチン(DFMO)は、ヒト前立腺におけるポリアミンレベルを抑制する
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
US9072778B2 (en) 2005-12-20 2015-07-07 University Of Hawaii Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
WO2010077653A2 (en) 2008-12-08 2010-07-08 The Procter & Gamble Company Personal care composition in the form of an article having a hydrophobic surface-resident coating
PT2430452E (pt) 2009-05-14 2014-09-30 Univ Arizona State Diagnóstico e tratamentos de carcinoma com base no genótipo odc1
CA2799431A1 (en) 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
LT2912193T (lt) 2012-10-29 2018-12-27 Arizona Board Of Regents On Behalf Of University Of Arizona Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi

Also Published As

Publication number Publication date
US9937141B2 (en) 2018-04-10
CN102483415A (zh) 2012-05-30
CA2761946A1 (en) 2010-11-18
US8329636B2 (en) 2012-12-11
ES2507145T3 (es) 2014-10-14
EP2430452B1 (en) 2014-06-25
JP6083860B2 (ja) 2017-02-22
US20190038584A1 (en) 2019-02-07
US20100317708A1 (en) 2010-12-16
AU2010248803A1 (en) 2011-12-01
IL216369A0 (en) 2012-01-31
US9121852B2 (en) 2015-09-01
EP2430452A1 (en) 2012-03-21
HRP20140887T1 (hr) 2014-11-21
EP2430452A4 (en) 2013-03-06
US20160213634A1 (en) 2016-07-28
JP2016074672A (ja) 2016-05-12
SI2430452T1 (sl) 2014-11-28
CN102483415B (zh) 2015-09-09
US20130164751A1 (en) 2013-06-27
PL2430452T3 (pl) 2014-12-31
IL216369B (en) 2018-07-31
DK2430452T3 (da) 2014-10-06
HK1171082A1 (en) 2013-03-15
AU2010248803B2 (en) 2014-05-29
PT2430452E (pt) 2014-09-30
WO2010132817A1 (en) 2010-11-18
JP2012526852A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
SMT201400177B (it) Diagnosi e trattamenti di carcinoma basati sul genotipo di odc1
EP2465446A4 (en) TREATMENT INSTRUMENT FOR ENDOSCOPE
HRP20140009T1 (hr) Dijagnosticiranje fetalne kromosomske aneuploidije uporabom genomskog sekvencijskog postupka
HUE064745T2 (hu) Módszerek és készítmények a rák diagnosztizálására és kezelésére
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
EP2391971A4 (en) NON-INVASIVE DIAGNOSTIC SYSTEM
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
FI20086175L (fi) Alus
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
FI20085782A0 (fi) Kartonkikone
EP2465593A4 (en) METHOD OF TREATING WATER AND FLOCCULATING WATER TREATMENT
EP2334085A4 (en) IMAGING PROCESSOR
EP2110789A4 (en) PAPER MONEY PROCESSOR
PL2613798T3 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
DK2173831T3 (da) Brøndbehandling
BRPI1012156A2 (pt) instrumento endoscópico.
FI20095396A0 (fi) Alus
BRPI1008674A2 (pt) Métodos de redução do desenvolvimento de pragas resistentes.
EP2440937A4 (en) A diagnostic method
DE602009000449D1 (de) Bildprozessor für Endoskope und Bildverarbeitungsverfahren für Endoskope
FR2955177B1 (fr) Structure orientable du type endoscope